Cognitive function and salivary cortisol levels were longitudinally examined in 52 patients with major depression before and after 3 weeks of standardized selective serotonin reuptake inhibitor (SSRI) and an add-on treatment modulating the mineralocorticoid receptor and compared to a healthy control group (n = 50) matched for age, gender and years of education.
Across add-on treatment groups, SSRI treatment reduced salivary cortisol in patients to levels of healthy controls (time 脳 group interaction p = .05). In patients, reduction of cortisol significantly correlated with improvement in depressive symptoms (r = .52, p < .01), speed of information processing (r = .50, p < .01), and cognitive set-shifting (r = .34, p = .03). Improved depressive symptoms were only associated with improved attention and working memory.
Improvement of some cognitive domains during SSRI treatment was associated with decreasing cortisol secretion and was only to a lesser extent associated with improved depressive symptoms.